Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.37 |
| ▸ | F3 | P13726 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15491101 | 0.85 | CSNK2A1 (0.50) | NOTUMCSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL353039 | 0.81 | BRPF1 (0.44) | NOTUMKDM4EGAAHPGDHSD17B10 | |
| SCHEMBL6023948 | 0.79 | NOTUM (0.46) | NOTUMCSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL2804501 | 0.79 | NOTUM (0.65) | NOTUMCSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL28944544 | 0.77 | NOTUM (0.50) | NOTUMCSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL9400147 | 0.76 | NR4A2 (0.49) | KDM4EGAA | |
| SCHEMBL1078596 | 0.74 | NOTUM (0.42) | NOTUMCSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL27695803 | 0.74 | HCAR2 (0.43) | NOTUMCSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL7116182 | 0.74 | CCNC (0.47) | NOTUMCSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL10937546 | 0.73 | AKR1C3 (0.48) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509453-B2 | BRM/BRG1 inhibitors and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-12-30 | — | — | US | disclosed |
| CN-115335373-B | Compounds and uses thereof | 福宏治疗公司 | 2025-05-20 | — | — | CN | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| CN-115335373-A | Compound and use thereof | 福宏治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-04-21 | — | — | US | disclosed |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2020160100-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| CN-1752157-A | Ink-jet ink sets, ink-jet ink tanks, ink-jet recording methods, and ink-jet recording apparatuses | FUJI XEROX CO LTD (JP) | 2006-03-29 | — | — | CN | disclosed |
| US-20060061640-A1 | Ink-jet ink sets, ink-jet ink tanks, ink-jet recording methods, and ink-jet recording apparatuses | FUJI XEROX CO., LTD. | 2006-03-23 | — | — | US | disclosed |
| US-20060061641-A1 | Inkjet printing method and image forming apparatus | FUJI XEROX CO., LTD. | 2006-03-23 | — | — | US | disclosed |
| US-20060023042-A1 | Liquid composition for ink jet, ink set for ink jet, ink jet recording method and ink jet recording apparatus | FUJI XEROX CO., LTD. | 2006-02-02 | — | — | US | disclosed |
| CN-1727413-A | Liquid composition for ink jet, ink set for ink jet, ink jet recording method and ink jet recording apparatus | FUJI XEROX CO LTD (JP) | 2006-02-01 | — | — | CN | disclosed |
| CN-1715052-A | Ink jet recording method and ink jet recording apparatus | FUJI XEROX CO LTD (JP) | 2006-01-04 | — | — | CN | disclosed |
| US-20050264630-A1 | Ink jet recording method and ink jet recording apparatus | FUJI XEROX CO., LTD. | 2005-12-01 | — | — | US | disclosed |
| US-20050259138-A1 | Ink jet recording method and ink jet recording apparatus | FUJI XEROX CO., LTD. | 2005-11-24 | — | — | US | disclosed |
| US-20050166792-A1 | Ink set for ink-jet recording, ink-jet recording method and ink-jet recording apparatus | FUJI XEROX CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| US-20040244645-A1 | Ink set for ink jet recording, ink jet recording method and ink jet recording apparatus | FUJI XEROX CO., LTD. (JP) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | NOTUM 3778/4885CSNK2A1 802/4885CSNK2A2 588/4885 |
| US-12509453-B2 | BRM/BRG1 inhibitors and uses thereof | SMARCC1, SMARCC2, SMARCA1 | NOTUM 4278/4885CSNK2A1 272/4885CSNK2A2 349/4885 |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | NOTUM 3559/4885CSNK2A1 942/4885CSNK2A2 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.